Genomenon, Inc. to Participate in BIO 2025 in Boston to Highlight Real World Evidence for Precision Therapeutics
Members of the leadership team will participate in BIO One-on-One Partnering™ meetings as their software, data, and consulting solutions support the diagnosis of rare diseases and drive targeted drug discovery.
Ann Arbor, MI - June 12, 2025 - FOR IMMEDIATE RELEASE
Genomenon, Inc., a leading provider of AI-driven genomic intelligence, is pleased to announce that senior members of its leadership and business development teams will be attending the 2025 BIO International Convention in Boston, taking place June 16-19 at the Boston Convention & Exhibition Center.
Genomenon's Vice President of Pharma Business Development, Dave Anstey, and Senior Pharmaceutical Account Manager, Ted King, will be available throughout the event to meet with biopharma partners and technology collaborators. Meetings can be scheduled directly through the BIO 1x1 Partnering System, which facilitates targeted, one-on-one conversations with industry leaders and innovators.
The company's Real World Evidence (RWE) for Precision Therapeutics leverages the company’s AI-powered knowledge graph to extract real-world data (RWD) from scientific literature. This data is then curated by a team of over 100 expert scientists into actionable RWE datasets. This comprehensive approach transforms previously inaccessible data into actionable insights, enabling refined disease-prevalence estimates, genotype-phenotype correlation, and clarifying patient demographics and treatment outcomes. These insights can be used to optimize clinical trial design, enhance diagnostic patient yield and streamline regulatory submissions.
“We’re excited to connect with companies at BIO who are focused on advancing precision medicine,” said Dave Anstey. “Our RWE delivers critical insights needed to accelerate drug development and improve patient outcomes. BIO offers the perfect venue to explore strategic collaborations.”
ABOUT GENOMENON
Genomenon is a leading genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world’s premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights. Genomenon's integrated software, data, and services solutions empower clients with advanced patient diagnosis and precision medicine development.
ABOUT BIO INTERNATIONAL CONVENTION
The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.
In a time of remarkable discovery and progress, the biotechnology industry stands at the forefront of a revolution changing how we live, heal, and care. From pioneering treatments offering hope to millions, to sustainable agricultural innovations to feed a growing population, or environmental breakthroughs securing our future, biotech drives positive change faster than ever. This progress is not just a change but a promise for a brighter future. The world is ready.
Whether you work at a public pharmaceutical company, biotech startup, academia, non-profit organization, or government agency; or you work as a researcher, business development professional or investor, BIO is where you'll make valuable connections and build relationships. Our proprietary BIO Partnering™ match-making platform-exclusive to the Premier Access registration package-allows you to find potential partners, schedule and accept meetings.
Genomenon Media Contact: Colleen McMillen, VP, Marketing
cmcmillen@genomenon.com
